Suivre
Binyamin Zhitomirsky
Binyamin Zhitomirsky
Postdoctoral associate, Broad institute of MIT and Harvard
Adresse e-mail validée de broadinstitute.org
Titre
Citée par
Citée par
Année
Lysosomes as mediators of drug resistance in cancer
B Zhitomirsky, YG Assaraf
Drug Resistance Updates 24, 23-33, 2016
4052016
Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance
B Zhitomirsky, YG Assaraf
Oncotarget 6 (2), 1143, 2015
2242015
Lysosomal accumulation of anticancer drugs triggers lysosomal exocytosis
B Zhitomirsky, YG Assaraf
Oncotarget 8 (28), 45117, 2017
1382017
Lysosomotropic drugs activate TFEB via lysosomal membrane fluidization and consequent inhibition of mTORC1 activity
B Zhitomirsky, A Yunaev, R Kreiserman, A Kaplan, M Stark, YG Assaraf
Cell death & disease 9 (12), 1191, 2018
1032018
LysoTracker and MitoTracker Red are transport substrates of P‐glycoprotein: implications for anticancer drug design evading multidrug resistance
B Zhitomirsky, H Farber, YG Assaraf
Journal of cellular and molecular medicine 22 (4), 2131-2141, 2018
692018
The role of cytoplasmic-to-lysosomal pH gradient in hydrophobic weak base drug sequestration in lysosomes
B Zhitomirsky, YG Assaraf
Cancer Cell & Microenvironment 2 (3), 2015
192015
The 5′ arm of Kluyveromyces lactis telomerase RNA is critical for telomerase function
MM Kabaha, B Zhitomirsky, I Schwartz, Y Tzfati
Molecular and cellular biology 28 (6), 1875-1882, 2008
192008
Protein-coated corrole nanoparticles for the treatment of prostate cancer cells
M Soll, QC Chen, B Zhitomirsky, PP Lim, J Termini, HB Gray, YG Assaraf, ...
Cell death discovery 6 (1), 1-17, 2020
182020
Correction: Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance
B Zhitomirsky, YG Assaraf
Oncotarget 13, 585, 2022
12022
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–9